Cancer chemotherapy and pharmacologyHumansAfatinibAntineoplastic AgentsCarcinomaNon-Small-Cell Lung
Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review.
Yu Yan, Xin Zheng, Xue Zhao, Xiaoyan Si, Li Zhang
Published: 202510.1007/s00280-025-04845-x
Abstract
Afatinib, an irreversible ErbB family inhibitor, is approved for the treatment of non-small cell lung cancer (NSCLC) with both common and selected uncommon EGFR mutations. Evidence in end-stage renal disease (ESRD) patients undergoing hemodialysis (H…
Preview only. Read the full abstract at the source